Diabetes Care, Vol 21, Issue 7 1117-1121, Copyright © 1998 by American Diabetes Association

ARTICLES

Postmenopausal estrogens and risk of myocardial infarction in diabetic women

RC Kaplan, SR Heckbert, NS Weiss, PW Wahl, NL Smith, KM Newton and BM Psaty
Cardiovascular Health Research Unit, University of Washington, Seattle 98101, USA. rkaplan@u.washington.edu

OBJECTIVE: The effect of hormone replacement therapy on the risk of myocardial infarction in diabetic women has not been well studied. We conducted a case-control study of postmenopausal estrogen use and risk of incident myocardial infarction (MI) in pharmacologically treated diabetic women enrolled at Group Health Cooperative of Puget Sound, a large health maintenance organization in the state of Washington. RESEARCH DESIGN AND METHODS: Case subjects (n = 212) were all postmenopausal women with treated diabetes who sustained an incident fatal or nonfatal MI between July 1986 and December 1994. Control subjects (n = 122) were treated diabetic women drawn from a stratified random sample of postmenopausal women without prior MI. Computerized pharmacy data and medical records were used to measure use of estrogens. Cardiovascular risk factors recorded from medical records, computerized pharmacy and laboratory data, and telephone interviews were used as adjustment variables. RESULTS: In this study 8.5% of case and 13.9% of control subjects were current users of estrogens. The relative risk (RR) of MI for current estrogen users was 0.51 (95% CI 0.22-1.15) relative to never users, adjusted for age, study year, weight, angina, and duration of treated diabetes. Among current estrogen users, risk of MI tended to decline with each additional year of estrogen use (adjusted RR = 0.78, 95% CI 0.56-1.08). Of those studied, 45.3% of case and 37.7% of control subjects were past users of estrogens (adjusted RR = 1.22, 95% CI 0.71-2.09). CONCLUSIONS: This study suggests that use of postmenopausal estrogens does not increase risk of MI in diabetic women and that sustained use may be of benefit.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Garbe and S. Suissa Issues to debate on the Women's Health Initiative (WHI) study: Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies Hum. Reprod., January 1, 2004; 19(1): 8 - 13. [Abstract] [Full Text] [PDF]

				K. M. Newton, A. Z. LaCroix, S. R. Heckbert, L. Abraham, D. McCulloch, and W. Barlow Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2810 - 2816. [Abstract] [Full Text] [PDF]

				E. Barrett-Connor Diabetes and Heart Disease Diabetes Care, October 1, 2003; 26(10): 2947 - 2958. [Full Text] [PDF]

				K.-H. Mak and S. M Haffner Diabetes abolishes the gender gap in coronary heart disease Eur. Heart J., August 1, 2003; 24(15): 1385 - 1386. [Full Text] [PDF]

				A. Ferrara, C. P. Quesenberry, A. J. Karter, C. W. Njoroge, A. S. Jacobson, and J. V. Selby Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes: The Northern California Kaiser Permanente Diabetes Registry, 1995-1998 Circulation, January 7, 2003; 107(1): 43 - 48. [Abstract] [Full Text] [PDF]

				K. E. Friday, C. Dong, and R. U. Fontenot Conjugated Equine Estrogen Improves Glycemic Control and Blood Lipoproteins in Postmenopausal Women with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 48 - 52. [Abstract] [Full Text]

				I. C. D. Westendorp, B. A. in't Veld, D. E. Grobbee, H. A. P. Pols, W. T. Meijer, A. Hofman, and J. C. M. Witteman Hormone Replacement Therapy and Peripheral Arterial Disease: The Rotterdam Study Arch Intern Med, September 11, 2000; 160(16): 2498 - 2502. [Abstract] [Full Text]

				C. Varas-Lorenzo, L. A. Garcia-Rodriguez, S. Perez-Gutthann, and A. Duque-Oliart Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction : A Population-Based Nested Case-Control Study Circulation, June 6, 2000; 101(22): 2572 - 2578. [Abstract] [Full Text] [PDF]

				I. C. D. Westendorp, B. A. I.’t Veld, M. L. Bots, J. M. Akkerhuis, A. Hofman, D. E. Grobbee, and J. C. M. Witteman Hormone Replacement Therapy and Intima-Media Thickness of the Common Carotid Artery : The Rotterdam Study Stroke, December 1, 1999; 30(12): 2562 - 2567. [Abstract] [Full Text] [PDF]

				B. Guerci, H. Antebi, L. Meyer, V. Durlach, O. Ziegler, J.-P. Nicolas, L.-G. Alcindor, and P. Drouin Increased Ability of LDL from Normolipidemic Type 2 Diabetic Women to Generate Peroxides Clin. Chem., September 1, 1999; 45(9): 1439 - 1448. [Abstract] [Full Text] [PDF]

				J. R. Kaseta, D. F. Skafar, J. L. Ram, S. J. Jacober, and J. R. Sowers Cardiovascular Disease in the Diabetic Woman J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1835 - 1838. [Abstract] [Full Text]

				E. M. Brooks-Asplund, A. A. Shoukas, S.-Y. Kim, S. A. Burke, and D. E. Berkowitz Estrogen has opposing effects on vascular reactivity in obese, insulin-resistant male Zucker rats J Appl Physiol, May 1, 2002; 92(5): 2035 - 2044. [Abstract] [Full Text] [PDF]